LAS VEGAS - Feb. 11, 2019 - TelAve -- TRICCAR Holdings, Inc., aka, TRICCAR, today announced Alden Townsend has joined TRICCAR's Scientific Advisory Board.

Alden Townsend began his career as a research geneticist with the USDA Agricultural Research Service in Ohio and later worked at the USDA's National Arboretum facility in Maryland. His responsibilities have included the improvement of urban plant species such as such as elm, red maple, spruce, alder, and hemlock. His work in developing a disease-resistant elm captured national attention. He started by making scores of controlled pollinations between European and Asiatic elms, germinating the seed, growing hybrid saplings, and inoculating them with the disease-causing fungus for the further testing of tolerance or resistance. A long-term process of cloning and screening followed.

Townsend has developed and released nine of the ten elm cultivars resistant to Dutch elm disease, and six red maple cultivars that are more adaptive to urban environments. He has also conducted extensive research on resistance of plants to insects, air pollutants, deicing salts, and drought. He has published more than 100 scientific and popular articles and provided leadership in various professional organizations including the International Society of Arboriculture, the Central States Forest Tree Improvement Council, the Metropolitan Tree Improvement Alliance, the Save the Elms Task Force, and Elm Watch.

More on TelAve News

• Productiv Doubles Capacity in Richmond to Support Growth
• New DC Energy Analyzer Charges Up on Kickstarter
• CentralAir.com Working with Local Real Estate Agencies to Help Replace AC Units on Home Purchases
• Securitize Partners with C Block Capital to Bridge Traditional and Digital Capital Markets in China
• OFFICIAL NOMINEES for the 6th Annual Reality TV Awards Announced!
• Azaleas, Wisteria and Roses: Japan's Other Spring Flowers
• XOV opens its doors to Asia and partners with ABCC Exchange

Townsend holds a B. S. in Forest Science from Penn State University, an M.F. in genetics and ecology from Yale and a Ph.D. in forest genetics and plant breeding from Michigan State University. He is a member of Xi Sigma Pi (forestry honor society) and Gamma Sigma Delta (agricultural honor society), and has honored with awards for Arboricultural Research from the International Society of Arboriculture, the USDA Agricultural Research Service, the Jackson Dawson Memorial Medal from the Massachusetts Horticultural Society, an honor award from the Secretary of Agriculture, and the Luther Burbank Award from the American  Horticultural Society for "extraordinary achievements in plant breeding.

"Dr. Townsend's experience in plant genetics and breeding will play a vital role in the expansion of TRICCAR's plant-based research for bioceuticals and pharmaceuticals," said Katrina Yao, EVP and CFO. "As further commitment to our 'White Knight' strategy to provide the world's finest naturally-derived disease treatments, having Dr. Townsend's outstanding experience as part of our Scientific Advisory Board is another step in delivering low cost over-the-counter bioceuticals and FDA-approved drugs to hundreds of millions of consumers around the world."

More on TelAve News

• Memorial Vigil set for NYPD Det Brian Simonsen 102 PCT killed in the line of duty, of his performance, robbery gone bad
• A "Couple of White Chicks at the Hairdresser" to be featured on Sofy.TV
• Long-term results with the Tat vaccine point to a new approach for a functional cure of HIV
• Origami in the Garden, A Traveling Exhibition Unfolding in Three Garden Locations in 2019
• Diane & The Deductibles Open For The Legendary Fabulous Thunderbirds at The Canyon Club in Agoura Hills on February 23rd!
• Entrepreneur Reveals Secret Formula to Making Millions
• Wisconsin Video Provider Moving to InnoStream™ MG-TV

TRICCAR is a Las Vegas, Nevada-based bioceutical company creating treatments that support the health of those suffering from the world's most common diseases, including, obesity, cancer, pain, diabetic neuropathy, calcium deficiency, and trigeminal neuralgia. The Company competes in markets estimated at $1 trillion in annual sales for human and animal formulations.

For additional information on TRICCAR, please visit http://www.triccar.com.